Federal abortion surveillance mandate buried in access-restriction bill

What it does

This bill prohibits the federal government from declaring a public health emergency related to abortion and immediately terminates any such declaration currently in effect. It also reinstates the requirement that mifepristone (the abortion pill) be dispensed only in person at clinics, medical offices, or hospitals under a doctor's supervision—reversing the FDA's 2023 relaxation of that rule—and blocks the FDA from loosening these restrictions unless all states submit detailed abortion surveillance data to the CDC, including maternal demographics and abortion method.

Why we flagged it

The bill's operative mechanism is twofold: (1) it blocks federal emergency declarations on abortion and reinstates in-person dispensing rules for mifepristone, directly restricting access to medication abortion; (2) it conditions any future FDA regulatory flexibility on mandatory state abortion surveillance data collection, creating a de facto surveillance and access-restriction regime.

• Mandatory abortion surveillance data collection (Section 3(c)) with detailed demographic and clinical variables is substantively unrelated to the bill's stated purpose of prohibiting emergency declarations and reinstating dispensing rules. It functions as a separate regulatory control mechanism.

What the text implies

• The mandatory abortion surveillance system (Section 3(c)) creates a federal database of abortion procedures linked to maternal demographics, race, ethnicity, and marital status—data that could be subpoenaed, leaked, or weaponized against women and providers in states with abortion bans or criminal penalties.
• By conditioning any future FDA regulatory flexibility on complete state abortion data submission, the bill effectively gives states veto power over federal drug policy and creates pressure on states to criminalize or restrict abortion reporting to avoid triggering federal surveillance requirements.
• The reinstatement of in-person dispensing requirements disproportionately affects rural women, low-income women, and women in states with geographic or financial barriers to clinic access, potentially forcing continuation of unwanted pregnancies.
• The bill's definition of 'abortion' (Section 3(d)(1)) includes language about 'whether the child survived the abortion,' which may be interpreted to criminalize or surveil miscarriage management and ectopic pregnancy treatment depending on state law.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill restricts access to medication abortion by reinstating in-person dispensing requirements and blocking FDA regulatory flexibility, making abortion care less accessible and more burdensome for patients, particularly those in rural areas or with limited mobility. It also mandates invasive state-level abortion surveillance data collection that may chill reporting and create privacy risks for women seeking care.

Who stands to gain

• anti-abortion advocacy organizations
• crisis pregnancy centers
• pharmaceutical companies with competing contraceptive/fertility products

Named in the bill

HHS Secretary, FDA Commissioner, CDC, mifepristone (RU-486), Public Health Service Act (Section 319, 319F-3), Federal Food, Drug, and Cosmetic Act (Section 505-1), Risk Evaluation and Mitigation Strategy (REMS), Bristol Myers Squibb (BMY), Genentech/Roche (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

25 cosponsors: 25 Republicans.

• Feb 24, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 24, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.